Eli Lilly And Co (NYSE:LLY) Shares Sold by Koshinski Asset Management Inc.

Koshinski Asset Management Inc. lowered its stake in shares of Eli Lilly And Co (NYSE:LLY) by 2.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,988 shares of the company’s stock after selling 73 shares during the quarter. Koshinski Asset Management Inc.’s holdings in Eli Lilly And Co were worth $491,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Cpwm LLC increased its position in shares of Eli Lilly And Co by 0.7% during the first quarter. Cpwm LLC now owns 9,349 shares of the company’s stock worth $1,297,000 after purchasing an additional 65 shares in the last quarter. Old North State Trust LLC grew its stake in Eli Lilly And Co by 1.2% during the 2nd quarter. Old North State Trust LLC now owns 5,660 shares of the company’s stock worth $929,000 after buying an additional 66 shares during the last quarter. Endurance Wealth Management Inc. increased its position in Eli Lilly And Co by 1.6% during the second quarter. Endurance Wealth Management Inc. now owns 4,141 shares of the company’s stock worth $680,000 after buying an additional 66 shares during the period. Parcion Private Wealth LLC lifted its stake in Eli Lilly And Co by 3.5% in the second quarter. Parcion Private Wealth LLC now owns 1,929 shares of the company’s stock valued at $322,000 after buying an additional 66 shares during the last quarter. Finally, Clifford Swan Investment Counsel LLC boosted its holdings in shares of Eli Lilly And Co by 1.3% in the first quarter. Clifford Swan Investment Counsel LLC now owns 5,289 shares of the company’s stock valued at $734,000 after acquiring an additional 70 shares during the period. Institutional investors own 77.32% of the company’s stock.

Eli Lilly And Co stock opened at $150.29 on Friday. The stock’s 50 day moving average price is $160.88 and its 200 day moving average price is $148.62. Eli Lilly And Co has a 1-year low of $101.36 and a 1-year high of $170.75. The company has a market cap of $143.74 billion, a PE ratio of 24.40, a price-to-earnings-growth ratio of 1.32 and a beta of 0.26. The company has a debt-to-equity ratio of 4.37, a current ratio of 1.11 and a quick ratio of 0.86.

Eli Lilly And Co (NYSE:LLY) last released its earnings results on Thursday, July 30th. The company reported $1.89 EPS for the quarter, beating analysts’ consensus estimates of $1.58 by $0.31. Eli Lilly And Co had a return on equity of 200.78% and a net margin of 24.48%. The company had revenue of $5.50 billion during the quarter, compared to the consensus estimate of $5.77 billion. During the same quarter last year, the company earned $1.50 earnings per share. Eli Lilly And Co’s quarterly revenue was down 2.4% compared to the same quarter last year. On average, equities research analysts anticipate that Eli Lilly And Co will post 7.3 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a dividend of $0.74 per share. This represents a $2.96 dividend on an annualized basis and a yield of 1.97%. The ex-dividend date is Thursday, August 13th. Eli Lilly And Co’s dividend payout ratio is currently 49.01%.

LLY has been the subject of several research reports. UBS Group downgraded shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and upped their price target for the company from $157.00 to $158.00 in a research report on Monday, April 20th. Cowen increased their target price on shares of Eli Lilly And Co from $145.00 to $160.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 15th. JPMorgan Chase & Co. boosted their price target on Eli Lilly And Co from $175.00 to $190.00 and gave the company an “overweight” rating in a research report on Wednesday, June 17th. Guggenheim raised Eli Lilly And Co from a “neutral” rating to a “buy” rating and set a $182.00 price objective for the company in a research report on Tuesday, June 16th. Finally, ValuEngine lowered Eli Lilly And Co from a “hold” rating to a “sell” rating in a report on Saturday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Eli Lilly And Co has a consensus rating of “Buy” and a consensus target price of $168.58.

In other news, major shareholder Lilly Endowment Inc sold 53,770 shares of the business’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $161.54, for a total transaction of $8,686,005.80. Following the sale, the insider now owns 111,798,270 shares of the company’s stock, valued at approximately $18,059,892,535.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Alfonso G. Zulueta sold 11,000 shares of the business’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $170.00, for a total value of $1,870,000.00. Following the sale, the senior vice president now directly owns 18,646 shares in the company, valued at approximately $3,169,820. The disclosure for this sale can be found here. Insiders have sold 555,236 shares of company stock worth $91,393,391 over the last 90 days. 0.09% of the stock is currently owned by company insiders.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: Understanding Average Daily Trade Volume

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.